沙滩上的崩塌

<正> 亚洲金融危机的爆发至今已有一年多的时间,从企业本身的角度来讲,是什么原因促成了金融危机的爆发与蔓延?曾盛极一时的亚洲家族式的经营模式有何弊病?中国资本市场以及包括商业银行在内的金融市场应     

Using IT Effectively in R&D Management23—25 September 1996, IMD, Lausanne, Switzerland

The commercialization of biotechnology requires very serious and intense research capabilities. The pharmaceutical industry has been one of the early exploiters of biotechnology because of the existence of such capabilities. This feature has been observed worldover and the literature is replete with information on how firms have evolved various strategies to meet this requirement. The present paper is an attempt to assess the R&D capabilities in the pharmaceutical companies in India in the context of biotechnology commercialization. A study was made of the R&D capabilities of 33 companies. These companies represent 3 categories of the Indian industry: purely medicinal chemistry based pharmaceuticals; diversified (both medicinal chemistry and biotechnology); dedicated biotechnology companies. Discriminant analysis was performed (i) to understand the distinctiveness of the three groups of companies and (ii) to understand the characteristics of their R&D capabilities. With respect to eight of the ten chosen parameters like R&D intensity, skill intensity, linkages, output of R&D, size, age, R&D manpower as a proportion of total manpower and number of skilled R&D employees, the three groups are observed to be distinct from each other.     

Motivation in sport and exercise: a comparison between the BRSQ and BREQ

Quality & Quantity - This study aimed to test whether the Behavioral Regulation in Sport Questionnaire and the Behavioral Regulation in Exercise Questionnaire can measure the same constructs in...